Prefer Sun Pharma, Lupin on correction: Ambareesh Baliga

Ambareesh Baliga, Independent Market Expert told CNBC-TV18, "I don't track too many of the midcap pharma stocks but then when it comes to the larger ones the US FDA has created decent amount of issues for most of them and we have seen what has happened to Dr Reddy's which has actually fallen off the buy radar for most of the analysts but I will still possibly look at something like Sun Pharma and Lupin on correction."Sun Pharmaceutical Industries ended at Rs 768.60, up Rs 10.55, or 1.39 percent.